Literature DB >> 11975851

Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy.

Yamina Hamel1, Neil Blake, Susanne Gabrielsson, Tracey Haigh, Karin Jooss, Chantal Martinache, Sophie Caillat-Zucman, Alan B Rickinson, Salima Hacein-Bey, Alain Fischer, Marina Cavazzana-Calvo.   

Abstract

Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (Ad) cause significant morbidity and mortality in immunocompromised patients undergoing allogeneic stem cell transplantation. We have established a procedure to generate polyclonal cytotoxic T lymphocyte (CTL) populations with specificity against Ad and CMV or against Ad and EBV. Healthy donor-derived dendritic cells (DCs) were transduced with recombinant adenovirus encoding either CMV pp65 or EBV EBNA3C and used to stimulate autologous T cells. Stimulated T lymphocytes displayed specific simultaneous cytotoxicity against CMV and adenovirus and to a lesser extent against adenovirus and EBV. Recombinant vaccinia virus encoding individual adenovirus proteins showed that the T cell response to the adenovirus was directed mainly against the capsid protein hexon. The frequency of IFN-gamma-secreting T cells was 0.02% for adenovirus alone, and 0.05 and 0.14% for adenoviruses encoding EBNA3C and pp65, respectively. pp65-specific CTLs killed autologous fibroblasts infected with the laboratory strain CMV AD169. The culture conditions were specific as alloreactive T cells were not expanded. Therefore, this approach could be considered in order to generate efficient virus cytolytic T cells to be used as adoptive immunotherapy in transplanted patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11975851     DOI: 10.1089/10430340252899028

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

1.  Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Authors:  Lawrence G Lum; Mayur Ramesh; Archana Thakur; Subhashis Mitra; Abhinav Deol; Joseph P Uberti; Philip E Pellett
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-05       Impact factor: 5.742

2.  Shortening the immunodeficient period after hematopoietic stem cell transplantation.

Authors:  Isabelle André-Schmutz; Emmanuelle Six; Delphine Bonhomme; Julien Rouiller; Liliane Dal Cortivo; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

3.  Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection.

Authors:  Maarten L Zandvliet; J H Frederik Falkenburg; Ellis van Liempt; Louise A Veltrop-Duits; Arjan C Lankester; Jayant S Kalpoe; Michel G D Kester; Dirk M van der Steen; Maarten J van Tol; Roel Willemze; Henk-Jan Guchelaar; Marco W Schilham; Pauline Meij
Journal:  Haematologica       Date:  2010-06-18       Impact factor: 9.941

4.  Compromised mitochondrial quality control triggers lipin1-related rhabdomyolysis.

Authors:  Yamina Hamel; François-Xavier Mauvais; Marine Madrange; Perrine Renard; Corinne Lebreton; Ivan Nemazanyy; Olivier Pellé; Nicolas Goudin; Xiaoyun Tang; Mathieu P Rodero; Caroline Tuchmann-Durand; Patrick Nusbaum; David N Brindley; Peter van Endert; Pascale de Lonlay
Journal:  Cell Rep Med       Date:  2021-08-17

Review 5.  Treatment of adenovirus infections in the immunocompromised host.

Authors:  P Ljungman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-10       Impact factor: 3.267

Review 6.  Cytotoxic T lymphocytes as immune-therapy in haematological practice.

Authors:  Ann M Leen; Helen E Heslop
Journal:  Br J Haematol       Date:  2008-08-07       Impact factor: 6.998

7.  Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy.

Authors:  Bianca Heemskerk; Louise A Veltrop-Duits; Tamara van Vreeswijk; Monique M ten Dam; Sebastiaan Heidt; Rene E M Toes; Maarten J D van Tol; Marco W Schilham
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Authors:  Ann M Leen; Anne Christin; Mariam Khalil; Heidi Weiss; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

9.  The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines.

Authors:  Kong-Wee Ong; A Douglas Wilson; Timothy R Hirst; Andrew J Morgan
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 10.  Gene and cell therapy for children--new medicines, new challenges?

Authors:  Karen F Buckland; H Bobby Gaspar
Journal:  Adv Drug Deliv Rev       Date:  2014-02-28       Impact factor: 15.470

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.